Please login to the form below

Not currently logged in
Email:
Password:

Spectrum appoints chief medical officer

Lee Allen joins from AMAG Pharmaceuticals

Lee Allen, SpectrumDr Lee Allen has joined cancer-focused Spectrum Pharmaceuticals as chief medical officer.

Dr Allen will lead the development of the US-based biotech's pipeline of products, including its investigational cancer drug belinostat, which is due to be filed for approval in mid-2013.

The appointment is a return to oncology for Dr Allen following a six-year spell as chief medical officer at AMAG Pharmaceuticals – the developer of Feraheme (ferumoxytol) for the treatment of iron deficiency anaemia in adult patients with chronic kidney disease.

Prior to this period, he spent four years at Wyeth from 2003 to 2007, serving as VP of clinical R&D for oncology.

Earlier in his career, he also spent time as executive director, site therapeutic area leader for oncology at Pfizer and medical director of oncology and immunology at BASF's Knoll Pharmaceuticals.

"I am very excited to join Spectrum, which I believe has a very promising portfolio of late-stage compounds," said Dr Allen.

"The company has the prospect of being able to introduce two to three new anti-cancer products by 2015 or 2016.”

Dr Allen's predecessor as chief medical officer, Dr Steve Fruchtman, will remain at Spectrum in the newly created role of senior VP, haematology and oncology R&D.

19th March 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics